Lexicon Pharmaceuticals, Inc.
Key Metrics
- Previous Close
- $1.78
- 52-Week Range
- $1.10 – $2.68
- Market Cap
- $765.80M
- P/E (TTM)
- —
- EPS (TTM)
- -0.15
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 4.67
- PEG Ratio
- -13.77
- Return on Equity
- -43.91%
- Return on Assets
- -15.85%
- Gross Margin
- 91.40%
- Operating Margin
- -147.42%
- Profit Margin
- -161.80%
- Current Ratio
- 10.63
- Debt/Equity
- 0.36
- Total Debt
- $59.54M
- Free Cash Flow
- $-27.89M
- Revenue Growth
- -20.70%
- Earnings Growth
- —
- Enterprise Value
- $642.14M
Market Snapshot
About
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing precision medicines for serious chronic conditions. The company markets Xermelo for carcinoid syndrome diarrhea and has a pipeline addressing cardiovascular, metabolism, and other therapeutic areas. Lexicon utilizes its proprietary gene knockout technology platform to identify and validate novel drug targets.